Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by MannKind
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
June 22, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
June 05, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
May 29, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
May 08, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
May 06, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
May 01, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
April 30, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
April 29, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Repays Certain Debt Obligations
April 03, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Announces CFO Transition
March 26, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
March 11, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
March 05, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation Announces Participation at Upcoming Conferences
March 04, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
February 27, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
February 20, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
February 15, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
January 02, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
December 28, 2023
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation Reports 2023 Third Quarter Financial Results
November 07, 2023
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
November 06, 2023
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
October 31, 2023
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
October 30, 2023
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation Announces Participation at Upcoming Conferences
September 05, 2023
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation Reports 2023 Second Quarter Financial Results
August 07, 2023
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
August 01, 2023
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
July 31, 2023
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)
June 22, 2023
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer
May 24, 2023
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
May 10, 2023
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial Results
May 09, 2023
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.